Endonovo Therapeutics (OTCQB: ENDV), an innovative
biotechnology company, this morning announced the appointment of Steven Levin,
M.D., to its scientific advisory board. Per the update, Dr. Levin will assist
Endonovo to facilitate the SofPulse(R) introduction to healthcare facilities
and further develop the Electroceutical(TM) devices pipeline. “Dr. Levin’s vast
experience with novel therapies in the anesthesiology and pain management
field, as well as his strong research interest to improve clinical practice in
pain management, will be valuable scientific additions to Endonovo,” ENDV CEO
Alan Collier said in the news release. “As a leader in the field of pain
management, Steven will contribute valuable knowledge and expertise as we move
our programs forward.”
To view the full press release, visit http://ibn.fm/55AM6
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of
noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s
current portfolio of commercial and clinical-stage wearable electroceuticals
therapeutic devices addresses wound healing, pain, postsurgical pain and edema,
cardiovascular disease, chronic kidney disease and central nervous system
(“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions,
postconcussion syndrome and multiple sclerosis. The company’s noninvasive
electroceutical therapeutic device, SofPulse(R), using pulsed short-wave
radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the
palliative treatment of soft-tissue injuries and postoperative pain and edema,
and has CMS national coverage for the treatment of chronic wounds. The
company’s current portfolio of preclinical-stage electroceuticals therapeutic
devices address chronic kidney disease, liver disease nonalcoholic
steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”),
and ischemic stroke. The company’s noninvasive, wearable electroceuticals
therapeutic devices work by restoring key electrochemical processes that
initiate anti-inflammatory and growth-factor cascades necessary for healing to
occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment